Hannah Clarke

"The data from the QUILT 3.032 Quality of Life study suggest that many patients not only have a durable response but also report no decline in physical function, which is very important for these patients,” says Karim Chamie, MD.

"It adds to the evidence base that is building that shows that improving your fitness levels is a positive thing to do to reduce your risk of developing prostate cancer," says Kate A. Bolam Enarsson, PhD.

According to statistics provided by the AUA, 385 medical students and other applicants were matched across 148 urology residency training programs nationwide.

Data revealed that 49% of prostate cancer signups in clinical trials were among patients newly diagnosed with cancer, compared with 32% among patients with other solid tumors.

Iterum plans to resubmit a New Drug Application for oral sulopenem for the treatment of patients with uUTi in Q2 of 2024.

The clearance will initiate the phase 2 CELLVX-230 trial, which will assess the therapy in patients with prostate cancer with a high risk of recurrence following prostatectomy.

Overall, the pathological complete response rate among patients who received APL-1202 plus tislelizumab was 39%, compared with 21% among those who received tislelizumab alone.

Data showed that treatment with radical prostatectomy was associated with worse urinary incontinence but not worse sexual function compared with other treatment options, regardless of cancer risk.

Patients were less likely to choose active surveillance when their decision was influenced by their treatment goals of achieving “cure” or to “live longer,” or when they perceived their diagnosis of low-risk prostate cancer to be more serious.

The real-world study plans to enroll 500 patients who are utilizing the Leva Pelvic Health System, a non-invasive medical device to help women train and strengthen pelvic floor muscles.

The investigators at DSUI developed 4 recommended actions for urologists based on the findings from the survey: drive multidisciplinary collaboration, leverage technology excellence, bridge patient-urologist perspectives, and foster collaboration with general practitioners.

Overall, more than 78% of consumers were able to appropriately self-select to use avanafil using the drug facts label (DFL) and the assistive app, compared with 56% of consumers using the DFL alone.

Data showed a similar incidence of TEAEs and TRAEs between cycles 1-4 and cycles 5-6 of treatment with 177Lu-PSMA-617.

A phase 3 study is expected to initiate in 2024 to explore the safety and efficacy of UGN-103 in LG-IR-NMIBC.

“These [patient-reported outcome] data are supportive of the use of [enfortumab vedotin plus pembrolizumab] as a 1L therapy option for patients who are cisplatin-ineligible," write the authors.

Nadofaragene firadenovec received FDA approval in December 2022 for the treatment of patients with high-risk BCG-unresponsive NMIBC with carcinoma in situ with or without papillary tumors.

In total, the study plans to enroll approximately 100 BCG-unresponsive NMIBC CIS patients across 15 clinical study sites in the US and Canada.

"While preliminary in nature, these data provide a compelling rationale for consideration of PSMA PET as an alternative staging modality at the time of primary diagnosis," wrote the authors.

"While alkaline water products have a higher pH than regular water, they have a negligible alkali content–which suggests that they can't raise urine pH enough to affect the development of kidney and other urinary stones," says Roshan M. Patel, MD.

The phase 1/2 study is scheduled to commence in the first half of 2024.

The oral TRT study plans to enroll 20 male patients aged 18 to 49 years who meet the American Urological Association’s criteria for hypogonadism and who have not previously used TRT.

The coverage policy went into effect on December 28, 2023.

The facility will increase the production capacity of 177Lu-PSMA-617 to 250,000 doses in 2024 and beyond.

Immunotherapy initiation within 1 month of death for patients with renal cell carcinoma increased from 0.5% to 2.6% over the course of the study.

The phase 1/2a CYPIDES trial assessed the safety and preliminary efficacy of ODM-208 in heavily pretreated patients with metastatic castration-resistant prostate cancer.

The payment rate for the prostate cancer test went into effect on January 1, 2024.

"The future of quality measurement is multiple different inputs to give us the best picture possible of the care we provide," says Timothy D. Lyon, MD, FACS.

The open-label CaRe PC trial plans to enroll up to 30 adult patients with mCRPC, who will be treated across 3 dose levels of INKmune.

Overall, 39.1% of patients with malignant ureteral obstruction were referred to palliative care over the study period.

As the year comes to a close, we revisit some of this year’s top content on kidney stones.